Polyethylene Glycol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Polyethylene Glycol
- Polyethylene Glycol: From Osmotic Laxative Use to Congenital Ichthyosiform Erythroderma
Polyethylene Glycol: From Osmotic Laxative Use to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Polyethylene glycol (PEG, DB09287) is a well-known osmotic laxative and topical excipient/moisturizing base ingredient; no formal indication or mechanism-of-action record exists in this Evidence Pack. The TxGNN model predicts it may be effective for Congenital Ichthyosiform Erythroderma, but this is currently supported by 0 clinical trials and 0 publications — the score reflects only knowledge-graph topological similarity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file — no India/Taiwan registration or indication data; PEG is generally known as an osmotic laxative and topical excipient/moisturizing base |
| Predicted New Indication | Congenital Ichthyosiform Erythroderma |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, PEG is a large inert polymer commonly used as an osmotic laxative (draws water into the bowel lumen) and, in topical formulations, as an excipient/moisturizing base — its efficacy in these roles is well established, but there is no formal indication record in this Evidence Pack to compare against.
Congenital ichthyosiform erythroderma is a keratinization disorder characterized by impaired skin barrier function and abnormal scaling. The only plausible link between PEG and this disease is through its topical emollient/moisturizing properties, which could theoretically support skin barrier hydration in ichthyosis-type conditions — a symptomatic/adjunctive role rather than a disease-modifying one.
However, there is no pharmacological mechanism connecting PEG’s systemic laxative action (or its general excipient function) to keratinocyte differentiation or skin barrier repair pathways. The TxGNN score of 99.03% reflects graph-topology similarity within the knowledge graph rather than validated pharmacological plausibility, and should be interpreted with caution in the absence of any corroborating mechanistic, preclinical, or clinical data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature support (Evidence Level L5) and no confirmed mechanism of action linking PEG to keratinization disorders — the prediction rests solely on TxGNN graph-topology scoring, which is insufficient to justify further evaluation at this time.
To proceed, the following is needed:
- TFDA/India regulatory label data (warnings, contraindications) — currently blocking safety pre-screening (DG001)
- Confirmed mechanism of action for PEG (DG002), to assess biological plausibility against congenital ichthyosiform erythroderma
- Any preclinical or case-level evidence on topical PEG use in ichthyosis or related keratinization disorders
- Drug interaction (DDI) data, currently unavailable (query returned not_found)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.